Medical/Pharmaceuticals
Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-06-08 08:30
3263
First Patient Enrolled in SELUTION SLR IDE BTK Study
LEIPZIG, Germany, June 8, 2022 /PRNewswire/ -- The first patient has been
enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial
involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just
one week after receiving IDE approval.
2022-06-08 08:00
3628
Innovent Announces Phase 2 study of Mazdutide（IBI362） in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, June 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ot...
2022-06-08 08:00
4160
Frost & Sullivan Awards EBSCO Information Services for Delivering Innovative Solutions to Access Medical Research Information for Healthcare Providers
Clinical Decisions product suite from EBSCO earns recognition for modern evidence-based resources that support clinical decision-making, enhance patient satisfaction, and improve outcomes SAN ANTONIO, June 7, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical decision support syst...
2022-06-07 21:00
3149
Nature Scientific Reports to publish novel decentralized federated AI learning algorithm that connects globally distributed data silos containing private and poor-quality data
SAN FRANCISCO, June 7, 2022 /PRNewswire/ -- Nature Scientific Reports journal has published results of a new decentralized federated AI learning algorithm from Presagen that can train AI on data that is distributed globally, without having to move private data to a central location. The breakthro...
2022-06-07 20:38
2515
Molecular Stethoscope, Inc. announces new investment from the Alzheimer's Drug Discovery Foundation
Investment by the ADDF will accelerate the translation of Molecular Stethoscope's cf-mRNA liquid biopsy technology platform into products and services for the diagnosis and management of Alzheimer's disease SOUTH SAN FRANCISCO, Calif., June 7, 2022 /PRNewswire/ -- Molecular Stethoscope, a leadin...
2022-06-07 18:00
2127
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
2852
SCG Cell Therapy And A*STAR's IMCB Collaborate To Accelerate Clinical Translation of Immune Cell-based Therapy
* The collaboration agreement works toward accelerating the study of SCG's immunotherapy pipeline and candidates such as CAR-T, TCR-T therapies, antibodies, and vaccines. * SCG will contribute its proprietary technologies to the therapeutic development of immune cell-based therapy candidates....
2022-06-07 12:23
3840
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018
– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathway. – This Phase I study will evaluate the safety, pharmacology and prelim...
2022-06-07 11:34
3775
Pharmactive Enters Strategic Partnership with Nutraconnect for APAC
Pharmactive targets Asia Pacific Market with new collaboration
MADRID, June 7, 2022 /PRNewswire/ -- Pharmactive Biotech Products
2022-06-07 09:00
3054
CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022
* Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significant and clinically meaningful overall survival improvement in combination with chemotherapy for patients with treatment-naïve stage IV non-small cell lung cancer across both squamous and non-squamous ...
2022-06-07 08:02
4572
Innovent and AnHeart Jointly Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1-TKI) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
* In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. * In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. * In 12 patients with brain metastasis and measurable...
2022-06-07 08:00
4158
Telix Showcasing Innovation in Theranostics at SNMMI
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held inVancouver from June 11-14. Gallium-based pr...
2022-06-07 05:00
3147
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) FLORENCE, Ita...
2022-06-06 23:07
4362
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"
LONDON and HONG KONG, June 6, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter endedMarch 31, 2022. The Company recorded strong opera...
2022-06-06 21:55
6509
Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...
2022-06-06 21:00
3465
Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...
2022-06-06 21:00
3752
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ -- Medison Pharma
2022-06-06 19:00
2753
NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
* SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). * NeuroAiD was safe as add-on treatment in patients with severe SCI. * One third of patients improved on AS...
2022-06-06 18:07
3769
CPHI China opens for international partnering after China rises in CPHI Index
The CPHI China Hosted Buyer Programme is empowering new partnering in China
SHANGHAI, June 6, 2022 /PRNewswire/ -- CPHI & P-MEC China
2022-06-06 16:51
5411
Week's Top Stories
Most Reposted
CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 293 media titles]
2026-09-22 18:37
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 292 media titles]
2026-09-24 10:30
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 281 media titles]
2026-09-23 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 275 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
12576
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
11288
Dreame Technology Opens New Flagship Store at Suntec City, Expanding Smart Living Experience in Singapore
2026-09-25 18:33
10210
